Logo image of GHRS

GH RESEARCH PLC (GHRS) Stock Fundamental Analysis

NASDAQ:GHRS - Nasdaq - IE000GID8VI0 - Common Stock - Currency: USD

16.32  -1.67 (-9.28%)

Premarket: 16.15 -0.17 (-1.04%)

Fundamental Rating

2

GHRS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. GHRS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GHRS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year GHRS has reported negative net income.
In the past year GHRS has reported a negative cash flow from operations.
In the past 5 years GHRS always reported negative net income.
In the past 5 years GHRS always reported negative operating cash flow.
GHRS Yearly Net Income VS EBIT VS OCF VS FCFGHRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

With a decent Return On Assets value of -17.83%, GHRS is doing good in the industry, outperforming 65.05% of the companies in the same industry.
GHRS has a Return On Equity of -18.79%. This is in the better half of the industry: GHRS outperforms 72.58% of its industry peers.
Industry RankSector Rank
ROA -17.83%
ROE -18.79%
ROIC N/A
ROA(3y)-9.28%
ROA(5y)-19.49%
ROE(3y)-9.52%
ROE(5y)-22.79%
ROIC(3y)N/A
ROIC(5y)N/A
GHRS Yearly ROA, ROE, ROICGHRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GHRS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GHRS Yearly Profit, Operating, Gross MarginsGHRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for GHRS remains at a similar level compared to 1 year ago.
GHRS has a worse debt/assets ratio than last year.
GHRS Yearly Shares OutstandingGHRS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
GHRS Yearly Total Debt VS Total AssetsGHRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

GHRS has an Altman-Z score of 49.27. This indicates that GHRS is financially healthy and has little risk of bankruptcy at the moment.
GHRS has a better Altman-Z score (49.27) than 97.31% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that GHRS is not too dependend on debt financing.
GHRS's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. GHRS outperforms 59.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 49.27
ROIC/WACCN/A
WACCN/A
GHRS Yearly LT Debt VS Equity VS FCFGHRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

A Current Ratio of 15.83 indicates that GHRS has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 15.83, GHRS belongs to the top of the industry, outperforming 89.25% of the companies in the same industry.
GHRS has a Quick Ratio of 15.83. This indicates that GHRS is financially healthy and has no problem in meeting its short term obligations.
GHRS's Quick ratio of 15.83 is amongst the best of the industry. GHRS outperforms 89.25% of its industry peers.
Industry RankSector Rank
Current Ratio 15.83
Quick Ratio 15.83
GHRS Yearly Current Assets VS Current LiabilitesGHRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for GHRS have decreased by -0.13% in the last year.
EPS 1Y (TTM)-0.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-109.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -0.30% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-21.2%
EPS Next 2Y-29.73%
EPS Next 3Y-21.76%
EPS Next 5Y-0.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GHRS Yearly Revenue VS EstimatesGHRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
GHRS Yearly EPS VS EstimatesGHRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6 8 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GHRS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GHRS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GHRS Price Earnings VS Forward Price EarningsGHRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GHRS Per share dataGHRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

A cheap valuation may be justified as GHRS's earnings are expected to decrease with -21.76% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-29.73%
EPS Next 3Y-21.76%

More info and screens

0

5. Dividend

5.1 Amount

GHRS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GH RESEARCH PLC

NASDAQ:GHRS (2/4/2025, 8:00:01 PM)

Premarket: 16.15 -0.17 (-1.04%)

16.32

-1.67 (-9.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)02-27 2025-02-27/amc
Inst Owners58.95%
Inst Owner Change0%
Ins Owners40.39%
Ins Owner ChangeN/A
Market Cap849.13M
Analysts83.64
Price Target31.88 (95.34%)
Short Float %7.77%
Short Ratio8.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.55%
Min EPS beat(2)10.34%
Max EPS beat(2)14.75%
EPS beat(4)3
Avg EPS beat(4)14.29%
Min EPS beat(4)-1.32%
Max EPS beat(4)33.4%
EPS beat(8)6
Avg EPS beat(8)7.99%
EPS beat(12)10
Avg EPS beat(12)29.02%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.34%
EPS NQ rev (1m)-3.54%
EPS NQ rev (3m)-8.33%
EPS NY rev (1m)-1%
EPS NY rev (3m)4.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.48
P/tB 4.48
EV/EBITDA N/A
EPS(TTM)-0.79
EYN/A
EPS(NY)-1.14
Fwd EYN/A
FCF(TTM)-0.77
FCFYN/A
OCF(TTM)-0.77
OCFYN/A
SpS0
BVpS3.64
TBVpS3.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.83%
ROE -18.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-9.28%
ROA(5y)-19.49%
ROE(3y)-9.52%
ROE(5y)-22.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.1%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.83
Quick Ratio 15.83
Altman-Z 49.27
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)223.92%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-109.09%
EPS Next Y-21.2%
EPS Next 2Y-29.73%
EPS Next 3Y-21.76%
EPS Next 5Y-0.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-34.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.17%
EBIT Next 3Y-34.89%
EBIT Next 5Y1.03%
FCF growth 1Y-72.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-72.99%
OCF growth 3YN/A
OCF growth 5YN/A